Type 2 diabetes mellitus (T2DM) is a progressive cardiometabolic disease requiring durable glycemic control while minimizing treatment-related harms such as hypoglycemia and weight gain.¹ Over the last decade, treatment goals have expanded beyond glucose lowering to include cardiovascular and renal risk reduction, especially for individuals with established atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), or chronic kidney disease (CKD).¹ Consequently, “newer” oral antidiabetic drugs—most prominently SGLT2 inhibitors and DPP-4 inhibitors, and more recently the oral GLP-1 receptor agonist semaglutide—have shifted prescribing patterns away from older “conventional” agents such as sulfonylureas and thiazolidinediones when feasible.¹

 

Conventional oral drugs remain important. Metformin is widely accepted as foundational therapy because of efficacy, familiarity, and cost; however, many patients require add-on therapy over time.¹ Sulfonylureas provide potent early HbA1c reductions but are limited by hypoglycemia risk and weight gain, and concerns about long-term durability.² In parallel, TZDs improve insulin sensitivity but are constrained by edema/heart failure risk and skeletal harms (fractures), with weight gain being common. ^22,23The clinical challenge is therefore not only “how much HbA1c falls” but also how long glycemic control is sustained, what adverse events accrue over time, and whether therapy reduces (or inadvertently increases) cardio-renal events.

 

SGLT2 inhibitors lower plasma glucose through insulin-independent glycosuria and typically reduce weight and blood pressure; they have demonstrated consistent reductions in HF hospitalization and renal disease progression across multiple CVOTs and kidney trials, positioning them as preferred options in T2DM with HF/CKD risk.^4,6–8,11 Meta-analytic data also suggest superior glycemic durability compared with sulfonylureas when used as add-on to metformin.²

 

DPP-4 inhibitors provide modest glucose lowering with weight neutrality and a low intrinsic risk of hypoglycemia. Head-to-head evidence versus sulfonylureas (often on metformin background) has repeatedly shown less hypoglycemia and less weight gain, while major cardiovascular outcomes appear broadly neutral in large long-term trials and pooled analyses.^12,14

 

Oral semaglutide (the first oral GLP-1RA) adds another oral option with clinically meaningful HbA1c reduction and weight loss in PIONEER trials, including comparisons versus empagliflozin and sitagliptin.^17–20 While gastrointestinal adverse effects can limit tolerability, the class is valued where weight loss is a high priority.²¹

 

Given the breadth of evidence across RCTs, CVOTs, and systematic reviews, a focused meta-analysis and evidence synthesis comparing newer oral therapies against conventional oral agents is clinically relevant to optimize individualized care. This article summarizes comparative efficacy (HbA1c and durability), safety (hypoglycemia, infections, DKA, fractures), and cardiorenal outcomes using post-2015 evidence.^1–25

A systematic review and meta-analytic evidence synthesis was conducted following PRISMA principles. Evidence sources included: (i) head-to-head RCTs/meta-analyses comparing newer oral agents vs conventional oral drugs, (ii) CVOTs and renal outcome trials for SGLT2i and related agents, and (iii) high-quality observational comparative studies when randomized evidence was unavailable for specific safety endpoints. Search strategy (2016–2025) The evidence base was compiled from PubMed/Medline and major journal platforms for publications between January 1, 2016 and December 31, 2025 using combinations of terms: “SGLT2 inhibitor”, “DPP-4 inhibitor”, “oral semaglutide”, “sulfonylurea”, “metformin”, “pioglitazone”, “randomized trial”, “meta-analysis”, “cardiovascular outcomes”, “renal outcomes”, “hypoglycemia”, “genital infection”, and “ketoacidosis”. Priority was given to (a) head-to-head comparisons, (b) large CVOTs, and (c) meta-analyses with explicit methods. PICOS framework • Population: Adults (≥18 years) with T2DM, including subgroups with ASCVD/HF/CKD. • Intervention (newer oral drugs): SGLT2 inhibitors (e.g., canagliflozin, dapagliflozin, empagliflozin, ertugliflozin), DPP-4 inhibitors (e.g., sitagliptin, linagliptin), and oral semaglutide. • Comparator (conventional oral drugs): metformin background (common to most studies), sulfonylureas (e.g., glimepiride), thiazolidinediones (e.g., pioglitazone), or “standard care/placebo” where trials established safety and cardiorenal efficacy relevant to comparative benefit-risk. • Outcomes: o Efficacy: HbA1c change and long-term durability; body weight. o Safety: hypoglycemia; genital/urinary infections; DKA; volume depletion; fractures; edema/HF signals; gastrointestinal adverse effects. o Cardiorenal: MACE, HHF, kidney disease progression endpoints. • Study design: RCTs, CVOTs, kidney outcome trials, and systematic reviews/meta-analyses; select large observational comparative studies were used to complement RCT evidence for rare harms. Inclusion criteria 1. Published 2016–2025. 2. Compared at least one newer oral class to a conventional oral drug or provided clinically decisive cardiorenal outcome estimates for SGLT2i relevant to comparative benefit. 3. Reported at least one prespecified outcome (HbA1c, weight, hypoglycemia, MACE/HHF, kidney outcomes, key adverse events). 4. Adult T2DM population with clear intervention/comparator definitions. Exclusion criteria • Non-human studies; narrative reviews without reproducible methods; pediatric or type 1 diabetes–only studies; trials without extractable comparative outcome data; duplicate publications (most complete/updated dataset retained). Data handling and synthesis approach Effect estimates were extracted as reported (mean differences for continuous outcomes; risk ratios/hazard ratios for binary/time-to-event outcomes). Where multiple high-quality meta-analyses existed for the same comparison, the most recent and methodologically comprehensive estimate was prioritized. Results are presented as pooled estimates (from included meta-analyses) or trial hazard ratios (from CVOTs), with interpretation emphasizing consistency across evidence streams.2,4–8,11,14,17–23 Risk of bias assessment. Because the evidence base combined primary trials with previously published systematic reviews, a tiered appraisal was applied. Randomized controlled trials and cardiovascular/renal outcome trials were assessed with the Cochrane Risk of Bias 2 (RoB 2) tool across its five domains: the randomization process, deviations from intended interventions, missing outcome data, measurement of the outcome, and selection of the reported result. Non-randomized comparative studies used to complement trial evidence for rare harms were appraised with ROBINS-I. Included systematic reviews and meta-analyses were appraised with AMSTAR-2 to judge the confidence warranted in each as an evidence source. Two reviewers independently rated each study, with disagreements resolved by discussion or a third reviewer. Each RoB 2 study received an overall judgment of low risk, some concerns, or high risk; AMSTAR-2 ratings were categorized as high, moderate, low, or critically low confidence. Certainty of evidence (GRADE). The certainty of evidence for each critical outcome was rated using the GRADE approach as high, moderate, low, or very low. Bodies of evidence from randomized trials began as high certainty and were rated down for risk of bias, inconsistency, indirectness, imprecision, or publication bias, and observational evidence could be rated up for a large effect. Ratings were made per outcome rather than per study, and a summary-of-findings table was produced.